Blinklab Limited (ASX:BB1)

Mr Brian Leedman is an experienced biotechnology entrepreneur with over 15 years’ experience in the biotechnology industry. Mr Leedman is the founder of ResApp Health Limited where Mr Leedman served as the executive director of corporate affairs. ResApp Health Limited was acquired by Pfizer (Aust) in 2022. Mr Leedman is an experienced public company director having formerly been the chairman of Neurotech International Limited, Nutritional Growth Solutions Limited, Neuroscientific Biopharmaceuticals Limited and was a director of Alcidion Corporation Limited, Oncosil Medical Limited and Respiri Limited.

Dr Uvarov has significant experience in the healthcare industry with a particular focus on neuroscience. Dr Uvarov has started his career in biotechnology investments as equities analyst with Citigroup. He is a co-founding director of several publicly listed companies in Australia including clinical stage companies such as Dimerix (ASX:DXB), Actinogen Medical (ASX:ACW) and Neuroscientific Biopharmaceuticals (ASX:NSB). He was previously on the board of Imugene (ASX:IMU), a late-stage clinical oncology company.

Ms Jane Morgan is a founder and director of JMM, a boutique investor relations and media communications consultancy group, that for over 16 years, has been providing strategic investor and media relations services to ASX listed companies, across a diverse range of industries including mining and resources, food and beverage, technology, SaaS, fintech, biotech and consumer goods.

Dr Bernier brings a rare combination of clinical practice, internationally recognised research leadership and commercial product-development experience1. His appointment is intended to deepen the Board’s expertise as BlinkLab progresses its pivotal U.S. FDA 510(k) program for BlinkLab Dx1 and prepares for clinical adoption and commercialisation in the United States, subject to regulatory clearance.

Dr Bernierbrings first-hand experience translating clinical science into digital products at global scale, including leading clinical development of Apple’s Mental Wellbeing app for iPhone, iPad and Apple Watch.

Dr Bernier is the former Executive Director of the Seattle Children’s Autism Center, one of the largest autism clinical programs in the United States, and former William J. and Lydia N. Gumerman Endowed Chair in Child Psychiatry at the University of Washington, bringing direct experience of autism clinical care and the diagnostic pathway that BlinkLab Dx1 is designed to support.

Dr Bernier has authored more than 200 scientific articles and two books, and has served as principal or co-investigator on more than 40 NIH and foundation-funded studies on the causes and neuroscience of autism and related neurodevelopmental disorders.